Burosumab in Unidentifiable Tumor‐Induced Osteomalacia

Clinical Case Reports 2026 Open access

Read full text
Authors: Yi Shan Der, Santosh Kumar Chaubey, Anna McLean, Yasmin Trinh, Ms. Shelley Pember, Ashim Kumar Sinha
DOI: 10.1002/ccr3.71600
Cited by: 0
References: 17

Abstract

Tumor-induced osteomalacia (TIO) can be challenging due to underlying tumors being either unresectable or unidentifiable. Burosumab, an anti-FGF23 monoclonal antibody, has been proven to be effective in treating TIO but is currently not subsidized for this indication in Australia. Our experience suggests that burosumab should be considered a first-line treatment.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Multiple Myeloma Research and Treatments Bone health and treatments

Publication details

Journal / source
Clinical Case Reports
Volume
14
Issue
1
Pages
e71600–e71600
Publication date
1 January 2026
Language
EN